5 active not recruiting, 3 recruiting, 1 completed, 1 not yet recruiting. 13 Phase 2, 7 Phase 1, 2 Phase 3.
Follow Advanced Malignant Neoplasm: new trials by email Literature Review of Advanced Malignant Neoplasm trials Research Report on Advanced Malignant Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors IAP0971 - Advanced Malignant Neoplasm, Advanced or Metastatic Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | SUNHO（China）BioPharmaceutical CO., Ltd. | 78 | 2024-12-31 | 2025-01-15 |
| A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors QLF31907, Irinotecan, Docetaxel - Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 60 | 2024-06-15 | 2024-05-01 |
| A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm Intravenous Infusion - Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Unknown | Mabwell (Shanghai) Bioscience Co., Ltd. | 272 | 2021-09-27 | 2022-05-09 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II - Advanced Malignant Neoplasm, Breast Cancer | Phase 1 / Phase 2 | Recruiting | AtlasMedx, Incorporated | 122 | 2020-08-12 | 2025-05-01 |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Ziftomenib, Midazolam, Itraconazole - Advanced Malignant Neoplasm, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | Kura Oncology, Inc. | 263 | 2019-09-12 | 2026-05-13 |
| Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Advanced Malignant Neoplasm, ALK Fusion Protein Expression | Phase 2 | Withdrawn | Sameek Roychowdhury | 2019-03-20 | 2022-02-18 | |
| Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer Chlorpromazine, Haloperidol, Quality-of-Life Assessment - Advanced Malignant Neoplasm, Delirium | Phase 2 / Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 70 | 2017-06-05 | 2026-09-14 |
| Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer Ethyl Icosapentate, Exercise Intervention, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Fatigue | Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2017-03-16 | 2021-06-10 |
| Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Vimseltinib - Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 120 | 2017-02-16 | 2026-06-25 |
| Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer Dexamethasone, Exercise Intervention, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Fatigue | Phase 2 / Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 90 | 2015-08-13 | 2026-09-22 |
| Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - Advanced Malignant Neoplasm, ATM Gene Mutation | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 150 | 2014-12-22 | 2026-06-12 |
| Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab Doxycycline, Management of Therapy Complications, Placebo - Advanced Malignant Neoplasm, Dermatologic Complication | Phase 2 | Completed | Academic and Community Cancer Research United | 19 | 2012-08-31 | 2020-01-09 |
Neoplasm Metastasis (5) · Neoplasms (3) · Recurrence (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Fatigue (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Brain Neoplasms (1) · Colorectal Neoplasms (1) · Delirium (1) · Disease Progression (1) · Endometrial Neoplasms (1) · Gallbladder Neoplasms (1) · Giant Cell Tumor of Tendon Sheath (1)
Pathological Conditions, Signs and Symptoms (7) · Neoplasms (6) · Pathologic Processes (6) · Neoplasms by Site (5) · Neoplastic Processes (5) · Disease Attributes (4) · Signs and Symptoms (3) · Adnexal Diseases (2) · Breast Diseases (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2)
Acetates (1) · Calcium Dobesilate (1) · Chlorpromazine (1) · Clinical Trials, Phase I as Topic (1) · Clinical Trials, Phase II as Topic (1) · Dexamethasone (1) · Docetaxel (1) · Doxycycline (1) · Haloperidol (1) · Hydrocortisone (1) · Infusions, Intravenous (1) · Irinotecan (1) · Itraconazole (1) · Midazolam (1) · Spironolactone (1)
M.D. Anderson Cancer Center (4) · Academic and Community Cancer Research United (1) · AtlasMedx, Incorporated (1) · Deciphera Pharmaceuticals, LLC (1) · Kura Oncology, Inc. (1) · Mabwell (Shanghai) Bioscience Co., Ltd. (1) · PMV Pharmaceuticals, Inc (1) · Qilu Pharmaceutical Co., Ltd. (1) · SUNHO（China）BioPharmaceutical CO., Ltd. (1) · Sameek Roychowdhury (1)
United States (10) · France (3) · Italy (3) · Spain (3) · Australia (2) · Canada (2) · China (2) · Germany (2) · United Kingdom (2) · Belgium (1) · Netherlands (1) · Poland (1) · Singapore (1) · South Korea (1)
Sriram Yennu (2) · Aminah Jatoi (1) · David Hui (1) · Jian Zhang, Professor (1) · Maitreyi Sharma, MD (1) · Marc Fellous, MD (1) · Pamela Munster, MD (1) · Sameek Roychowdhury, MD (1) · Sarina A Piha-Paul (1)
PMID 32479786, PMID 33741715, PMID 34267079, PMID 34965510, PMID 39362248, PMID 40543428, PMID 40932470, PMID 40997296, PMID 41740031
P30CA015083 (1), P30CA016058 (1), R21NR016736 (1)